ID
28373
Descrição
This trial will enroll approximately 6,000 patients with recent embolic stroke of unknown source (ESUS). Patients will be randomized to dabigatran or acetylsalicyclic acid (ASA) (1:1 ratio) and have visits every three months. The study doctor may prescribe blinded concomitant ASA for pts with coronary artery disease but this is not mandatory. All Adverse Events (AEs), Serious Adverse Events (SAEs), outcome events will be recorded. The trial will conclude when the required number of stroke events are positively adjudicated which is estimated to take 3 years (including 2.5 years of enrollment). Sponsor / Information provided by (Responsible Party): Boehringer Ingelheim. https://clinicaltrials.gov/ct2/show/NCT02239120?term=NCT02239120&cond=NCT02239120&rank=1
Link
https://clinicaltrials.gov/ct2/show/NCT02239120?term=NCT02239120&cond=NCT02239120&rank=1
Palavras-chave
Versões (1)
- 08/01/2018 08/01/2018 -
Titular dos direitos
Boehringer Ingelheim
Transferido a
8 de janeiro de 2018
DOI
Para um pedido faça login.
Licença
Creative Commons BY-NC 3.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility criteria RE-SPECT ESUS Embolic Stroke NCT02239120
Eligibility criteria RE-SPECT ESUS Embolic Stroke NCT02239120
- StudyEvent: ODM
Descrição
Exclusion criteria
Descrição
Modified Rankin Scale
Tipo de dados
boolean
Descrição
such as: a) intracardiac thrombus as evidenced by transthoracic or transesophageal echocardiography, b) paroxysmal, persistent or permanent AF, c) atrial flutter, d) prosthetic cardiac valve (mitral or aortic, bioprosthetic or mechanical), e) atrial myxoma, f) other cardiac tumors, g) moderate or severe mitral stenosis, h) recent (< 4weeks) myocardial infarction, i) valvular vegetations, or j) infective endocarditis
Tipo de dados
boolean
Descrição
anticoagulant
Tipo de dados
boolean
Descrição
History of atrial fibrillation
Tipo de dados
boolean
Descrição
i.e. cerebral arteritis or arterial dissection, migraine with aura/vasospasm, drug abuse
Tipo de dados
boolean
Descrição
Renal impairment with estimated creatinine clearance (as calculated by Cockcroft-Gault equation) <30mL/min at screening, or where Investigator expects creatinine clearance is likely to drop below 30mL/min during the course of the study
Tipo de dados
boolean
Similar models
Eligibility criteria RE-SPECT ESUS Embolic Stroke NCT02239120
- StudyEvent: ODM